Corosolic Acid lowers blood sugar significantly
Researchers from the Department of Diabetes and Clinical Nutrition at Kyoto
University gave 31 people either 10mg Corosolic Acid or inactive placebo a number
of times, 5 minutes before an oral glucose tolerance test consisting of drinking
75-g of sugar in water in a cross-over design. The test subjects had diabetes,
or impaired glucose tolerance, impaired fasting glucose, and 4 had normal sugar
activity. The Corosolic Acid lowered blood glucose within 60 minutes and reached
statistical significance by 90 minutes. The study is published in the August
2006 issue of the Irish medical journal Diabetes Research and Clinical Practice.
Corosolic Acid significantly improves blood sugar in type II diabetics
In this study type II diabetics who were not using insulin were supplemented
with Corosolic Acid for two weeks. The supplement significantly improved blood
sugar levels by 20% to 30%. The study is published in the July 2003 issue of
the Irish publication Journal of Ethnopharmacology.
Cinnamon improves glucose and lipids of people with type 2 diabetes
In this study 60 people with type 2 diabetes (30 mne/30 women) between the age
of 46 to 58 were given various dosages of Cinnamon or placebo for 40 days. Cinnamon
reduced fasting blood glucose by 18-29%, triglycerides by 23-30%, LDL-cholesterol
by 7-27%, and total cholesterol by 12-26%. There were no significant changes
in the placebo group. Using Cinnamon in patients with type 2 diabetes will reduce
risk factors associated with diabetes and cardiovascular disease. The study
is published in the December 2003 issue of the journal Diabetes Care.
Aqueous Extract of Cinnamon reduces fasting blood sugar in diabetics
on oral drugs
In this study 79 patients with Type 2 diabetes who were taking medication other
than insulin or on a strict diet were given an Aqueous Extract of Cinnamon corresponding
to 3 grams of Cinnamon a day for 4 months or an inactive placebo. The Cinnamon
Extract caused the fasting blood glucose to drop by 10.3% on average, far more
than placebo (3.4%). The study is published in the May 2006 issue of the European
Journal of Clinical Investigation.